JP2020503871A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020503871A5 JP2020503871A5 JP2019537074A JP2019537074A JP2020503871A5 JP 2020503871 A5 JP2020503871 A5 JP 2020503871A5 JP 2019537074 A JP2019537074 A JP 2019537074A JP 2019537074 A JP2019537074 A JP 2019537074A JP 2020503871 A5 JP2020503871 A5 JP 2020503871A5
- Authority
- JP
- Japan
- Prior art keywords
- virus
- inhibitors
- encoding
- protein
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241000700605 Viruses Species 0.000 claims description 87
- 108090000623 proteins and genes Proteins 0.000 claims description 41
- 239000003112 inhibitor Substances 0.000 claims description 28
- 206010028980 Neoplasm Diseases 0.000 claims description 27
- 230000037361 pathway Effects 0.000 claims description 27
- 239000000556 agonist Substances 0.000 claims description 17
- 239000002246 antineoplastic agent Substances 0.000 claims description 17
- 238000000034 method Methods 0.000 claims description 17
- 239000003814 drug Substances 0.000 claims description 14
- 229940045513 CTLA4 antagonist Drugs 0.000 claims description 12
- 239000012634 fragment Substances 0.000 claims description 12
- 230000003213 activating effect Effects 0.000 claims description 11
- 229940079593 drug Drugs 0.000 claims description 11
- 239000012275 CTLA-4 inhibitor Substances 0.000 claims description 10
- 102000004169 proteins and genes Human genes 0.000 claims description 10
- 201000011510 cancer Diseases 0.000 claims description 9
- 108010068327 4-hydroxyphenylpyruvate dioxygenase Proteins 0.000 claims description 7
- 239000003795 chemical substances by application Substances 0.000 claims description 7
- 108020004201 indoleamine 2,3-dioxygenase Proteins 0.000 claims description 7
- 102000006639 indoleamine 2,3-dioxygenase Human genes 0.000 claims description 7
- 241000713813 Gibbon ape leukemia virus Species 0.000 claims description 6
- 241000712079 Measles morbillivirus Species 0.000 claims description 6
- 241000700584 Simplexvirus Species 0.000 claims description 6
- 230000037430 deletion Effects 0.000 claims description 6
- 238000012217 deletion Methods 0.000 claims description 6
- 230000008488 polyadenylation Effects 0.000 claims description 6
- 108010029697 CD40 Ligand Proteins 0.000 claims description 5
- 102100032937 CD40 ligand Human genes 0.000 claims description 5
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims description 5
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 claims description 5
- 101100508081 Human herpesvirus 1 (strain 17) ICP34.5 gene Proteins 0.000 claims description 5
- 101150027249 RL1 gene Proteins 0.000 claims description 5
- 210000004027 cell Anatomy 0.000 claims description 5
- 241001430294 unidentified retrovirus Species 0.000 claims description 5
- 108090000288 Glycoproteins Proteins 0.000 claims description 4
- 102000003886 Glycoproteins Human genes 0.000 claims description 4
- 241001559185 Mammalian rubulavirus 5 Species 0.000 claims description 4
- 241000713821 Mason-Pfizer monkey virus Species 0.000 claims description 4
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 4
- 230000004927 fusion Effects 0.000 claims description 4
- 230000028993 immune response Effects 0.000 claims description 4
- 230000001939 inductive effect Effects 0.000 claims description 4
- 108091006086 inhibitor proteins Proteins 0.000 claims description 4
- 239000002773 nucleotide Substances 0.000 claims description 4
- 125000003729 nucleotide group Chemical group 0.000 claims description 4
- 244000309459 oncolytic virus Species 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 101150013553 CD40 gene Proteins 0.000 claims description 3
- 108010062802 CD66 antigens Proteins 0.000 claims description 3
- 102100024533 Carcinoembryonic antigen-related cell adhesion molecule 1 Human genes 0.000 claims description 3
- 102100031256 Cyclic GMP-AMP synthase Human genes 0.000 claims description 3
- 101710118064 Cyclic GMP-AMP synthase Proteins 0.000 claims description 3
- 206010064571 Gene mutation Diseases 0.000 claims description 3
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 claims description 3
- 101710083479 Hepatitis A virus cellular receptor 2 homolog Proteins 0.000 claims description 3
- 101000868279 Homo sapiens Leukocyte surface antigen CD47 Proteins 0.000 claims description 3
- 101000633784 Homo sapiens SLAM family member 7 Proteins 0.000 claims description 3
- 101000801234 Homo sapiens Tumor necrosis factor receptor superfamily member 18 Proteins 0.000 claims description 3
- 101000666896 Homo sapiens V-type immunoglobulin domain-containing suppressor of T-cell activation Proteins 0.000 claims description 3
- 102100034980 ICOS ligand Human genes 0.000 claims description 3
- 101710093458 ICOS ligand Proteins 0.000 claims description 3
- 102000017578 LAG3 Human genes 0.000 claims description 3
- 101150030213 Lag3 gene Proteins 0.000 claims description 3
- 102100032913 Leukocyte surface antigen CD47 Human genes 0.000 claims description 3
- 241000713869 Moloney murine leukemia virus Species 0.000 claims description 3
- 101000597780 Mus musculus Tumor necrosis factor ligand superfamily member 18 Proteins 0.000 claims description 3
- 102000004473 OX40 Ligand Human genes 0.000 claims description 3
- 108010042215 OX40 Ligand Proteins 0.000 claims description 3
- 239000012270 PD-1 inhibitor Substances 0.000 claims description 3
- 239000012668 PD-1-inhibitor Substances 0.000 claims description 3
- 239000012271 PD-L1 inhibitor Substances 0.000 claims description 3
- 102100029198 SLAM family member 7 Human genes 0.000 claims description 3
- 229940126547 T-cell immunoglobulin mucin-3 Drugs 0.000 claims description 3
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 3
- 102100033728 Tumor necrosis factor receptor superfamily member 18 Human genes 0.000 claims description 3
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 claims description 3
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 claims description 3
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 claims description 3
- 102100038282 V-type immunoglobulin domain-containing suppressor of T-cell activation Human genes 0.000 claims description 3
- 239000000427 antigen Substances 0.000 claims description 3
- 102000036639 antigens Human genes 0.000 claims description 3
- 108091007433 antigens Proteins 0.000 claims description 3
- 238000002512 chemotherapy Methods 0.000 claims description 3
- IJJVMEJXYNJXOJ-UHFFFAOYSA-N fluquinconazole Chemical compound C=1C=C(Cl)C=C(Cl)C=1N1C(=O)C2=CC(F)=CC=C2N=C1N1C=NC=N1 IJJVMEJXYNJXOJ-UHFFFAOYSA-N 0.000 claims description 3
- 230000002757 inflammatory effect Effects 0.000 claims description 3
- 230000037431 insertion Effects 0.000 claims description 3
- 238000003780 insertion Methods 0.000 claims description 3
- 208000032839 leukemia Diseases 0.000 claims description 3
- 239000003446 ligand Substances 0.000 claims description 3
- 210000000822 natural killer cell Anatomy 0.000 claims description 3
- 229940121655 pd-1 inhibitor Drugs 0.000 claims description 3
- 229940121656 pd-l1 inhibitor Drugs 0.000 claims description 3
- 238000001959 radiotherapy Methods 0.000 claims description 3
- 108010046080 CD27 Ligand Proteins 0.000 claims description 2
- 102100027207 CD27 antigen Human genes 0.000 claims description 2
- 108010017987 CD30 Ligand Proteins 0.000 claims description 2
- 241000713730 Equine infectious anemia virus Species 0.000 claims description 2
- 108091006027 G proteins Proteins 0.000 claims description 2
- 102000030782 GTP binding Human genes 0.000 claims description 2
- 108091000058 GTP-Binding Proteins 0.000 claims description 2
- 241000700588 Human alphaherpesvirus 1 Species 0.000 claims description 2
- 241001465754 Metazoa Species 0.000 claims description 2
- 101710169105 Minor spike protein Proteins 0.000 claims description 2
- 101710081079 Minor spike protein H Proteins 0.000 claims description 2
- 101800001693 R-peptide Proteins 0.000 claims description 2
- 108090000138 Tumor necrosis factor ligand superfamily member 15 Proteins 0.000 claims description 2
- 102100024587 Tumor necrosis factor ligand superfamily member 15 Human genes 0.000 claims description 2
- 102100032100 Tumor necrosis factor ligand superfamily member 8 Human genes 0.000 claims description 2
- 101150085955 US11 gene Proteins 0.000 claims description 2
- 208000007502 anemia Diseases 0.000 claims description 2
- 239000005557 antagonist Substances 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 108700014844 flt3 ligand Proteins 0.000 claims description 2
- 230000003308 immunostimulating effect Effects 0.000 claims description 2
- 238000000338 in vitro Methods 0.000 claims description 2
- 230000015788 innate immune response Effects 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 2
- 230000000241 respiratory effect Effects 0.000 claims description 2
- 238000002560 therapeutic procedure Methods 0.000 claims description 2
- 210000004881 tumor cell Anatomy 0.000 claims description 2
- 241000701161 unidentified adenovirus Species 0.000 claims description 2
- 241001529453 unidentified herpesvirus Species 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 4
- 241000714177 Murine leukemia virus Species 0.000 claims 2
- 230000001177 retroviral effect Effects 0.000 claims 2
- 229940041181 antineoplastic drug Drugs 0.000 claims 1
- 230000007699 co-inhibitory pathway Effects 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 239000012528 membrane Substances 0.000 claims 1
- 210000000056 organ Anatomy 0.000 claims 1
- 208000003265 stomatitis Diseases 0.000 claims 1
- 241000711975 Vesicular stomatitis virus Species 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 108010021064 CTLA-4 Antigen Proteins 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 description 1
- 241000282620 Hylobates sp. Species 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 230000007012 clinical effect Effects 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024050685A JP2024095709A (ja) | 2017-01-09 | 2024-03-27 | 改変ウイルス |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1700350.0 | 2017-01-09 | ||
| GBGB1700350.0A GB201700350D0 (en) | 2017-01-09 | 2017-01-09 | Altered virus |
| PCT/GB2018/050048 WO2018127713A1 (en) | 2017-01-09 | 2018-01-09 | Altered virus |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024050685A Division JP2024095709A (ja) | 2017-01-09 | 2024-03-27 | 改変ウイルス |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020503871A JP2020503871A (ja) | 2020-02-06 |
| JP2020503871A5 true JP2020503871A5 (cg-RX-API-DMAC7.html) | 2021-01-28 |
| JP7520511B2 JP7520511B2 (ja) | 2024-07-23 |
Family
ID=58463943
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019537074A Active JP7520511B2 (ja) | 2017-01-09 | 2018-01-09 | 改変ウイルス |
| JP2024050685A Pending JP2024095709A (ja) | 2017-01-09 | 2024-03-27 | 改変ウイルス |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024050685A Pending JP2024095709A (ja) | 2017-01-09 | 2024-03-27 | 改変ウイルス |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US12059444B2 (cg-RX-API-DMAC7.html) |
| EP (2) | EP3565568B1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP7520511B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20190104055A (cg-RX-API-DMAC7.html) |
| CN (1) | CN110198724B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2018205763B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112019013215A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3049496A1 (cg-RX-API-DMAC7.html) |
| DK (1) | DK3565568T3 (cg-RX-API-DMAC7.html) |
| ES (1) | ES3038026T3 (cg-RX-API-DMAC7.html) |
| GB (1) | GB201700350D0 (cg-RX-API-DMAC7.html) |
| IL (1) | IL267949B2 (cg-RX-API-DMAC7.html) |
| MX (2) | MX2019008146A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2018127713A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3400293B2 (en) | 2016-01-08 | 2023-07-12 | Replimune Limited | Modified oncolytic virus |
| AU2017212713B2 (en) | 2016-01-27 | 2023-01-19 | Oncorus, Inc. | Oncolytic viral vectors and uses thereof |
| RU2021127872A (ru) | 2016-06-30 | 2021-11-09 | Онкорус, Инк. | Доставка терапевтических полипептидов посредством псевдотипированных онколитических вирусов |
| GB201700350D0 (en) | 2017-01-09 | 2017-02-22 | Replimune Ltd | Altered virus |
| EA201992575A1 (ru) | 2017-04-28 | 2020-04-13 | Мерк Шарп И Доум Корп. | Биомаркеры для терапии рака |
| RU2771110C2 (ru) | 2017-07-26 | 2022-04-26 | Онкорус, Инк. | Онколитические вирусные векторы и их применение |
| PE20200867A1 (es) | 2017-08-03 | 2020-08-31 | Amgen Inc | Conjugados que comprende una muteina de interleucina 21 y un anticuerpo anti-pd-1 |
| JP7150823B2 (ja) | 2017-09-08 | 2022-10-11 | アムジエン・インコーポレーテツド | ＫＲａｓ Ｇ１２Ｃの阻害剤及びそれを使用する方法 |
| EP3731850A4 (en) | 2017-12-29 | 2021-12-01 | Oncorus, Inc. | ONCOLYTIC VIRUS DELIVERY OF THERAPEUTIC POLYPEPTIDES |
| CA3087273A1 (en) | 2018-01-12 | 2019-07-18 | Amgen Inc. | Anti-pd-1 antibodies and methods of treatment |
| CN109762068A (zh) * | 2018-08-09 | 2019-05-17 | 源道隆（苏州）医学科技有限公司 | 一种可靶向ctla4和pd-1的单基因双特异性抗体及其应用 |
| AU2019414450B2 (en) | 2018-12-27 | 2025-07-03 | Amgen Inc. | Lyophilized virus formulations |
| CA3131529A1 (en) | 2019-03-05 | 2020-09-10 | Amgen Inc. | Use of oncolytic viruses for the treatment of cancer |
| TW202102543A (zh) | 2019-03-29 | 2021-01-16 | 美商安進公司 | 溶瘤病毒在癌症新輔助療法中之用途 |
| CN113891747A (zh) * | 2019-05-15 | 2022-01-04 | 郑州威瑞生物技术有限公司 | 诱导免疫细胞活性的组合物及使用该组合物治疗疾病的方法 |
| CN110218707B (zh) * | 2019-05-29 | 2021-10-22 | 上海市公共卫生临床中心 | 一种新型溶瘤病毒及其制备方法和应用 |
| AU2020283592A1 (en) * | 2019-05-29 | 2022-01-20 | Orbis Health Solutions, Llc | Delivery vectors and particles for expressing chimeric receptors and methods of using the same |
| EP4013458A4 (en) * | 2019-08-16 | 2023-05-10 | Immvira Co., Limited | ONCOLYTIC HERPES SIMPLEX VIRUS PHARMACEUTICAL COMPOSITIONS FOR SYSTEMIC ADMINISTRATION |
| CN110982794B (zh) * | 2020-03-05 | 2020-06-16 | 北京唯源立康生物科技有限公司 | 一种修饰的单纯疱疹病毒 |
| CN110982795B (zh) * | 2020-03-05 | 2020-06-16 | 北京唯源立康生物科技有限公司 | 一种单纯疱疹病毒及其用途 |
| CN114075574A (zh) * | 2020-08-19 | 2022-02-22 | 广东东阳光药业有限公司 | 构建体、溶瘤病毒及其应用 |
| AU2023409819A1 (en) * | 2022-12-20 | 2025-08-07 | Janssen Biotech, Inc. | Oncolytic virus and uses thereof |
Family Cites Families (57)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU594014B2 (en) | 1984-03-21 | 1990-03-01 | Research Corporation Technologies, Inc. | Recombinant DNA molecules |
| US5288641A (en) | 1984-06-04 | 1994-02-22 | Arch Development Corporation | Herpes Simplex virus as a vector |
| CA1282721C (en) | 1984-06-04 | 1991-04-09 | Bernard Roizman | Herpes simplex virus as a vector |
| DE3584341D1 (de) | 1984-08-24 | 1991-11-14 | Upjohn Co | Rekombinante dna-verbindungen und expression von polypeptiden wie tpa. |
| US5168062A (en) | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
| US5698531A (en) | 1989-03-31 | 1997-12-16 | The Regents Of The University Of Michigan | Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor |
| US5328688A (en) | 1990-09-10 | 1994-07-12 | Arch Development Corporation | Recombinant herpes simplex viruses vaccines and methods |
| US6770274B1 (en) | 1990-09-14 | 2004-08-03 | The General Hospital Corporation | Viral mutant HSV mediated destruction of neoplastic cells |
| US6040169A (en) | 1991-01-31 | 2000-03-21 | Medical Research Council | Herpes simplex virus-1 deletion variants and vaccines thereof |
| DE69332525T2 (de) | 1992-03-31 | 2003-04-17 | Arch Development Corp., Chicago | Behandlung von Tumorerkrankungen mit modifiziertem HSV |
| US6699468B1 (en) | 1994-06-23 | 2004-03-02 | Georgetown University | Replication-competent herpes simplex virus mediates destruction of neoplastic cells |
| WO1997012623A1 (en) | 1995-10-06 | 1997-04-10 | Arch Development Corporation | Methods and compositions for viral enhancement of cell killing |
| US5824318A (en) | 1996-07-24 | 1998-10-20 | American Cyanamid Company | Avirulent herpetic viruses useful as tumoricidal agents and vaccines |
| GB9700411D0 (en) * | 1997-01-10 | 1997-02-26 | Univ London | Eukaryotic gene expression cassette and uses thereof |
| US6379674B1 (en) | 1997-08-12 | 2002-04-30 | Georgetown University | Use of herpes vectors for tumor therapy |
| US7300774B1 (en) | 1999-12-09 | 2007-11-27 | The Regents Of The University Of California | Multimeric fusion proteins of the TNF superfamily ligands |
| US6428968B1 (en) | 1999-03-15 | 2002-08-06 | The Trustees Of The University Of Pennsylvania | Combined therapy with a chemotherapeutic agent and an oncolytic virus for killing tumor cells in a subject |
| EP1227828A1 (en) | 1999-11-12 | 2002-08-07 | Oncolytics Biotech, Inc. | Viruses for the treatment of cellular proliferative disorders |
| BRPI0107736B8 (pt) | 2000-01-21 | 2021-05-25 | Biovex Ltd | cepa hsv1 js1, composição farmacêutica, e, uso de uma cepa hsv1 js1 |
| ES2366608T3 (es) | 2001-03-27 | 2011-10-21 | The General Hospital Corporation | Vectores víricos y su uso en métodos terapéuticos. |
| GB0317511D0 (en) | 2003-07-25 | 2003-08-27 | Biovex Ltd | Viral vectors |
| WO2006002394A2 (en) | 2004-06-24 | 2006-01-05 | New York University | Avirulent oncolytic herpes simplex virus strains engineered to counter the innate host response |
| RU2007114111A (ru) | 2004-11-04 | 2008-12-10 | Пфайзер Продактс Инк. (Us) | Лечение рака молочной железы с помощью комбинации антитела против ctla4 и ингибитора ароматазы |
| DK2620450T3 (en) | 2005-03-08 | 2019-02-04 | Pfizer Prod Inc | Antibody Compositions against CTLA-4 |
| CN101495126B (zh) | 2005-06-23 | 2016-01-06 | 休斯顿大学 | Ⅱ型单纯疱疹病毒突变体在治疗癌症中的用途 |
| GB0522476D0 (en) | 2005-11-03 | 2005-12-14 | Biovex Ltd | Oncolytic herpes virus vectors |
| JP6092497B2 (ja) | 2006-03-30 | 2017-03-08 | ユニバーシティー オブ カリフォルニア | 抗ｃｔｌａ−４抗体の限局性分泌のための方法および組成物 |
| WO2009148488A2 (en) | 2008-05-29 | 2009-12-10 | The General Hospital Corporation | Use of oncolytic herpes viruses for killing cancer stem cells |
| RU2573912C2 (ru) | 2008-10-08 | 2016-01-27 | Интрексон Корпорейшн | Сконструированные клетки, экспрессирующие множественные иммуномодуляторы, и их применения |
| US20100297072A1 (en) | 2009-05-19 | 2010-11-25 | Depinho Ronald A | Combinations of Immunostimulatory Agents, Oncolytic Virus, and Additional Anticancer Therapy |
| EP2502078A1 (en) | 2009-11-20 | 2012-09-26 | Infinity Pharmaceuticals, Inc. | Methods and compositions for treating hedgehog-associated cancers |
| WO2011119925A2 (en) | 2010-03-25 | 2011-09-29 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Synthetic herpes simplex viruses for treatment of cancers |
| WO2011118866A1 (ko) | 2010-03-26 | 2011-09-29 | 연세대학교 산학협력단 | 네트워크를 통한 심사요청 방법 |
| CA2812093A1 (en) | 2010-09-24 | 2012-03-29 | Oncos Therapeutics Oy | Oncolytic adenoviral vectors coding for monoclonal anti - ctla - 4 antibodies |
| FI20115914L (fi) | 2011-09-16 | 2013-03-17 | Oncos Therapeutics Ltd | Muunnettu onkolyyttinen virus |
| US10238698B2 (en) | 2012-01-25 | 2019-03-26 | Dnatrix, Inc. | Biomarkers and combination therapies using oncolytic virus and immunomodulation |
| KR20150038066A (ko) * | 2012-07-30 | 2015-04-08 | 알렉스 와 힌 영 | 종양 세포, 암세포파괴 바이러스 벡터 및 면역 체크포인트 조절인자를 갖는 암 백신 시스템 |
| CN114984062A (zh) | 2012-08-30 | 2022-09-02 | 安姆根有限公司 | 使用单纯疱疹病毒和免疫检查点抑制剂治疗黑色素瘤的方法 |
| WO2014066532A1 (en) | 2012-10-23 | 2014-05-01 | Bristol-Myers Squibb Company | Combination of anti-kir and anti-ctla-4 antibodies to treat cancer |
| WO2014128235A1 (en) | 2013-02-22 | 2014-08-28 | F. Hoffmann-La Roche Ag | Methods of treating cancer and preventing drug resistance |
| KR102222157B1 (ko) | 2013-03-14 | 2021-03-03 | 이칸 스쿨 오브 메디슨 엣 마운트 시나이 | 뉴캐슬병 바이러스 및 이의 용도 |
| JP6557234B2 (ja) | 2013-09-03 | 2019-08-07 | メディミューン リミテッド | 弱毒化ニューカッスル病ウイルスを特徴とする組成物並びに新生物を治療するための使用方法 |
| SI3021859T1 (en) * | 2013-10-25 | 2018-04-30 | Psioxus Therapeutics Limited | Oncolytic adenoviruses equipped with heterologous genes |
| PT3184641T (pt) | 2013-10-28 | 2020-08-21 | Univ Pittsburgh Commonwealth Sys Higher Education | Vetor de hsv oncolítico |
| JP2016540505A (ja) | 2013-11-22 | 2016-12-28 | ディーエヌエートリックス インコーポレイテッド | アデノウイルス発現免疫細胞刺激受容体アゴニスト |
| US10933106B2 (en) * | 2014-02-25 | 2021-03-02 | Deutsches Krebsforschungszentrum | RNA viruses for immunovirotherapy |
| MA39818A (fr) | 2014-03-30 | 2017-02-08 | Benevir Biopharm Inc | Virus oncolytiques « armés » comprenant un inhibiteur de tap exogène et leurs utilisations thérapeutiques |
| CA3190510A1 (en) * | 2014-07-16 | 2016-01-21 | Transgene Sa | Oncolytic virus for expression of immune checkpoint modulators |
| JP6843736B2 (ja) | 2014-07-16 | 2021-03-17 | トランジェーヌＴｒａｎｓｇｅｎｅ | 腫瘍溶解性ウイルスと免疫チェックポイントモジュレーターとの組合せ |
| US20160040186A1 (en) * | 2014-08-07 | 2016-02-11 | Xiaoyun Liu | Dna construct and method for transgene expression |
| GB201419579D0 (en) | 2014-11-03 | 2014-12-17 | Iomet Pharma Ltd | Pharmaceutical compound |
| CA2974529C (en) | 2015-01-23 | 2023-08-15 | Dreamwell, Ltd. | Automated mattress manufacturing process and apparatus |
| CN104987421A (zh) * | 2015-05-13 | 2015-10-21 | 北京比洋生物技术有限公司 | 抗ctla-4和pd-1的双重可变结构域免疫球蛋白 |
| EP3400293B2 (en) * | 2016-01-08 | 2023-07-12 | Replimune Limited | Modified oncolytic virus |
| AU2016403583B2 (en) * | 2016-04-22 | 2020-05-28 | Immvira Co., Limited | Construction of oncolytic herpes simplex viruses (oHSV) obligate vector and constructs for cancer therapy |
| GB201700350D0 (en) | 2017-01-09 | 2017-02-22 | Replimune Ltd | Altered virus |
| WO2019243847A1 (en) * | 2018-06-21 | 2019-12-26 | Replimune Limited | Treatment using oncolytic virus |
-
2017
- 2017-01-09 GB GBGB1700350.0A patent/GB201700350D0/en not_active Ceased
-
2018
- 2018-01-09 US US16/466,612 patent/US12059444B2/en active Active
- 2018-01-09 JP JP2019537074A patent/JP7520511B2/ja active Active
- 2018-01-09 DK DK18701924.5T patent/DK3565568T3/da active
- 2018-01-09 AU AU2018205763A patent/AU2018205763B2/en active Active
- 2018-01-09 CA CA3049496A patent/CA3049496A1/en active Pending
- 2018-01-09 ES ES18701924T patent/ES3038026T3/es active Active
- 2018-01-09 IL IL267949A patent/IL267949B2/en unknown
- 2018-01-09 BR BR112019013215-5A patent/BR112019013215A2/pt unknown
- 2018-01-09 EP EP18701924.5A patent/EP3565568B1/en active Active
- 2018-01-09 WO PCT/GB2018/050048 patent/WO2018127713A1/en not_active Ceased
- 2018-01-09 EP EP25186357.7A patent/EP4635984A3/en active Pending
- 2018-01-09 CN CN201880006355.8A patent/CN110198724B/zh active Active
- 2018-01-09 MX MX2019008146A patent/MX2019008146A/es unknown
- 2018-01-09 KR KR1020197023554A patent/KR20190104055A/ko not_active Ceased
-
2019
- 2019-07-05 MX MX2025002735A patent/MX2025002735A/es unknown
-
2024
- 2024-03-27 JP JP2024050685A patent/JP2024095709A/ja active Pending
- 2024-07-10 US US18/769,170 patent/US20240358781A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020503871A5 (cg-RX-API-DMAC7.html) | ||
| JP2019501671A5 (cg-RX-API-DMAC7.html) | ||
| JP2019501670A5 (cg-RX-API-DMAC7.html) | ||
| US20240358781A1 (en) | Altered virus | |
| US20230203453A1 (en) | Modified oncolytic virus | |
| JP2019500909A5 (cg-RX-API-DMAC7.html) | ||
| JP2024095709A5 (cg-RX-API-DMAC7.html) | ||
| AU2012322999B2 (en) | Combination medicament comprising IL-12 and an agent for blockade of T-cell inhibitory molecules for tumour therapy | |
| CN112020510B (zh) | 包含用于治疗癌症的肿瘤抑制基因疗法和cd122/cd132激动剂的方法及组合物 | |
| US20210252135A1 (en) | Treatment using oncolytic virus | |
| KR20190112263A (ko) | 암 및 감염성 질환의 치료 및 예방을 위한 바이러스 유전자 치료요법 및 면역 체크포인트 억제제를 포함하는 방법 및 조성물 | |
| JPWO2019243847A5 (cg-RX-API-DMAC7.html) | ||
| US20230270861A1 (en) | Inhibitors of the Artemin Pathway for Treatment of Cancer | |
| US20250121017A1 (en) | Oncolytic virotherapy compositions and methods | |
| HK40045432A (en) | Modified oncolytic virus | |
| HK40042181A (en) | Methods and compositions comprising tumor suppressor gene therapy and cd122/cd132 agonists for the treatment of cancer |